中文摘要：

目的：应用表面增强激光解析离子化一飞行时间一质谱（SEI。DI-TOF-MS）技术筛选不同分型的卵巢上皮性癌患者血清标志物。方法：选择卵巢上皮性癌68例，健康妇女87例，卵巢良性肿瘤组20例血清，以及体外培养的卵巢恶性肿瘤细胞系SKOV3、A2780、H08910、H08910PM为材料，采用WCX2蛋白质芯片分析血清和体外培养的恶性肿瘤细胞系蛋白质表达差异蛋白，选择卵巢上皮性癌血清与细胞均存在表达的差异蛋白建立卵巢上皮性癌诊断模型进行验证。结果：WCX2芯片捕获的M／Z为5343和5640蛋白质，在卵巢浆液性上皮癌和浆液性上皮癌细胞系H08910、H08910PM中均上调表达。以上述2个蛋白质建立诊断模型判别浆液性卵巢癌的敏感性为97．8％，特异性为82．7％，优于CA125的检测结果。结论：M／Z为5343和5640蛋白质在卵巢浆液性上皮癌发生和发展的过程中的变化可以反映到血清中，而且可以验证血清标志蛋白的组织特异性，为其作为卵巢癌的肿瘤标志物提供强有力的支持。

英文摘要：

Objective： To discover relatively specifically biomarkers in serum trom patients with different subtypes of epithelial ovarian cancer and in ovarian cancer cell lines by surface-enhanced laser desorption and ionization time of flight mass spectrometry technology. Methods：Serum samples were obtained from 87 healthy individuals, 68 patients with epithelial ovarian cancer,and 37 patients with benign tumor. Total proteins of cell were respectively derived from four kinds of epithelial ovarian cancer lines （A2780,SKOV3, HO8910 and HO8910PM）. Proteomic profiles of serum from ovarian caner and epithelial ovarian cancer lines were analyzed using WCX2 proteinchips. The proteins of distinct expression were detected and filtrate by Ciphergen Biomarker Wizard software, and used by Biomarker Patterns 5. 0 software. A diagnostic model of differential proteins from serum and cell lines has been developed for separating ovarian cancer from control group to confirm its values as a biomarker of ovarian cancer. Results：Two up-regulated proteins at M/Z 5 343 and 5 640 from serum of serous epithelial ovarian cancer were also discovered in HO8910 and HO8910PM cell lines. These potential biomarkers were established diagnostic model to discriminate serous epithelial ovarian cancer from non-cancer group. The model at sensitivity of 97.8% and specificity of 82. 7% which is statistically significantly better than CA125 with a cutoff 35 units/ml. Conclusion： The overexpressed proteins at M/Z 5 343 and 5 640 could be candidate biomarkers of serous epithelial ovarian cancer. They may be related with the occurrence and development of ovarian cancer.